• First next-generation sequencing platform to receive funding from BARDA

• Up to $51.9 million, contract to support testing and FDA clearance of DNAe’s sequencing platform for a series of applications

• Initial focus to address two of the most significant threats to global health, antimicrobial resistance and influenza

London, UK and Carlsbad, CA, USA – DNA Electronics (‘DNAe’), the inventors of semiconductor-based next-generation DNA sequencing (NGS) technology and developers of a revolutionary blood-to-result test for bloodstream infections, announces that the Biomedical Advanced Research and Development Authority (BARDA) a division of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS) has awarded the Company a contract worth up to $51.9 million to develop its sequencing platform for rapid diagnosis in two key applications; antimicrobial resistant infections and influenza.

Genomic informa